HC Wainwright Comments on MediWound FY2029 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of MediWound in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth anticipates that the biopharmaceutical company will post earnings of $2.45 per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the business earned ($0.19) EPS.

Other equities research analysts have also recently issued research reports about the stock. Craig Hallum started coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 price target on the stock. StockNews.com raised shares of MediWound to a “sell” rating in a report on Friday.

MediWound Stock Down 4.6 %

Shares of NASDAQ MDWD opened at $16.27 on Friday. MediWound has a twelve month low of $12.78 and a twelve month high of $24.00. The stock’s 50 day moving average price is $18.17 and its 200-day moving average price is $17.58. The company has a market capitalization of $175.49 million, a PE ratio of -5.61 and a beta of 0.82.

Institutional Investors Weigh In On MediWound

A number of institutional investors and hedge funds have recently made changes to their positions in MDWD. Bank of America Corp DE increased its stake in MediWound by 38.0% in the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 2,178 shares during the last quarter. Northern Trust Corp grew its stake in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after buying an additional 70,367 shares during the last quarter. MGO One Seven LLC bought a new position in shares of MediWound during the fourth quarter valued at about $216,000. Barclays PLC grew its stake in shares of MediWound by 11.2% during the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 1,249 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,162 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.